



Empowering Licensed Medical Professionals
With Intiva Token And A
Decentralized Credentialing Platform

INTIVA TOKEN



WHITE PAPER

03.26.2018
V 1.0

Shawn Frasquillo, John Hartigan, Garry McIntosh, Andrew Chapin


ABSTRACT

Satoshi Nakamoto's *Bitcoin: A Peer-to-Peer Electronic Cash System* sparked a revolution that seeks to leverage distributed ledger technology and cryptocurrencies to move beyond centralized financial infrastructure. There has been progress toward reaching this goal, as evidenced by the total market capitalization of cryptocurrencies exceeding six hundred billion USD (\$600,000,000,000) in 2017,¹ but this explosion in popularity only tells a fraction of the story. Distributed ledger technology will not only disrupt centralized financial infrastructures, but also nearly every market segment in the world.

The Intiva Health Platform (the "Platform") was built by Practice Interactive, LLC, dba Intiva Health (hereinafter, "Intiva Health"), the parent company of Intiva Token Inc., to automate the administrative tasks of credential and licensure management, continuing education coursework, and discovering job opportunities for healthcare professionals. Specifically, the Platform is intended to enable healthcare professionals to organize and maintain all the documents necessary to conduct their profession in compliance with all laws and regulations applicable to health care professionals. The Platform captures a valuable subset of data from the highest paid group of professionals in the United States and uses that data to give healthcare professionals more control over their careers.

Certain inefficiencies in healthcare have resulted in the loss of critical productive time and billions of dollars. Intiva Token, Inc. (the "Company") can further address these concerns by integrating the revolutionary Hashgraph distributed ledger technology ("DLT") and a tokenized (cryptocurrency) economy, with the existing business operations of Intiva Health.

¹ Global Charts, CoinMarketCap (2018), <https://coinmarketcap.com/charts/>



CONTENTS

ABSTRACT	2
CONTENTS	3
Statement of Purpose	4
Forward Looking Statements	4
Disclaimers	5
ORGANIZATION, BUSINESS, & PURPOSE	7
Organization & Current Operations	7
Business Model	8
Strategic Plan & Distributed Ledger Implementation	11
Hashgraph	12
Intiva Token (“NTVA”)	13
EMERGING TECHNOLOGY	14
Intiva ReadyDoc™	15
MARKET	19
ISSUANCE PLANS, TERMS & PARTICIPATION	20
The Company’s Share Offering	22
The Intiva Token Offering	23
TEAM & ADVISORS	34
CONTACT INFORMATION	36
ADDENDUMS	37
Addendum A: Intiva Health Credential Document Lifestyle	37
Addendum B: ReadyDoc™	38
Addendum C: Fragmentation	40
Addendum D: Roadmap and Milestones	41
Addendum E: Token Issuance Plan	43
Addendum F: Token Events	44

Statement of Purpose

This White Paper (the “White Paper”) is for informational purposes only and may be subject to change. This White Paper intends to inform prospective U.S. investors of shares in Intiva Token, Inc. (the “Company Shares”) (“Investors”), and prospective purchasers of Intiva Token (“NTVA”) (“Purchasers”)² about the operation of the Company, the Company’s relationship with Intiva Health, the services and products offered on the Intiva Health Platform, and NTVA’s utility on the Intiva Health Platform. There is sensitive information enclosed herein, and it is understood this White Paper will be used solely for the aforementioned purpose. This White Paper does not constitute an offer or solicitation of Company Shares or NTVA in any country, state, or other jurisdiction in which such an offer or solicitation is not authorized. The information contained in this White Paper is privileged, proprietary, and otherwise protected from disclosure. Each prospective Investor and Purchaser, by accepting delivery (electronically or physically) of this White Paper, agrees to the foregoing and undertakes not to reproduce, in whole or in part, this White Paper, or any documents relating thereto. If such prospective Investor or Purchaser does not purchase any of the Company Shares or NTVA, respectively, offered hereby or the Offering is terminated, the prospective Investor or Purchaser agrees to promptly return this White Paper and all such documents to the Company, if so required by the Company. If the reader of this White Paper is not the intended recipient, you are hereby notified that any dissemination, distribution, copying, or use of this White Paper is strictly prohibited. If you have received this document in error, please destroy any copy thereof.

Forward Looking Statements

Certain matters discussed in this White Paper constitute forward-looking statements. All statements that are not purely historical constitute “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. When used herein, the words “may,” “will,” “continue,” “anticipate,” “intend,” “estimate,” “believe,” “expect,” “should,” “potential,” “forecast,” “project,” variations of such words and similar expressions, or the negatives thereof are generally intended to identify forward-looking statements. Such forward-looking statements, including the intended actions and performance objectives of the Company, involve known and unknown risks, uncertainties, and other important factors that could cause the actual results, performance, or achievements of the Company to differ materially from any future results, performance, or achievements expressed or implied by such forward-looking statements. No representation or warranty is made as to future performance of such forward-looking statements. All forward-looking statements in this White Paper are based on management’s beliefs, as well as assumptions made by and information available to management and speak only as of the date hereof. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement contained herein to

² Note that tokens are *not offered for sale to any U.S. Persons*, as defined in Rule 902 of the Securities Act. Tokens may *only be purchased by non-U.S. Persons located outside of the United States*.

reflect any change in its expectation with regard thereto or any change in events, conditions, or circumstances on which any such statement is based. Forward-looking statements may be about future performance including, but not limited to, the future revenues, earnings, strategies, and prospects of the Company. Such forward-looking statements are subject to risks and uncertainties which could cause actual results to differ materially from those anticipated. Prospective Investors and Purchasers are cautioned not to place undue reliance on these forward-looking statements in making any personal decision. Prospective Investors and Purchasers are not to construe this White Paper as investment, tax, regulatory, financial, accounting, or other advice, and this White Paper is not intended to provide the sole basis for any evaluation of an investment in the Company. Prior to acquiring securities in the Company, a prospective Investor or Purchaser should consult its own legal, investment, tax, accounting, and other advisors to determine the potential benefits, burdens, and other consequences of such investment.

Disclaimers

It is the responsibility of any person wishing to subscribe to the shares described in this White Paper and the associated Offering Memorandum to inform themselves of and to observe all applicable laws and regulations of any relevant jurisdictions. Prospective Investors and Purchasers should inform themselves as to the legal requirements and tax consequences with respect to the acquisition, holding, or disposition of these securities.


The information currently provided within this White Paper does not purport to be complete and is subject to and qualified in its entirety by reference to the actual text of the Offering Memorandum and other relevant documents, copies of which shall be provided to each prospective Investor and Purchaser upon request.

All investments in the Company by U.S. Investors and purchase of NTVA by Non-U.S. Purchasers involve a high degree of risk, volatility, and illiquidity. A prospective Investor or Purchaser should thoroughly review the Offering Memorandum or Information Memorandum, respectively, upon its release and carefully consider whether an investment in the Company or purchase of the NTVA is suitable to the Investor or Purchaser's financial situation and goals. Prior to any investment or purchase, the Company will provide Investors and Purchasers the opportunity to ask additional questions and receive additional information from the Company concerning the terms and conditions of its offering and other relevant matters, to the extent the Company possesses the same or can acquire such information without unreasonable effort or expense. The Company makes no guarantee that any Investors in the Company's shares will receive a return of their capital or any returns on their investment. The Company also makes no representation that any Purchasers of NTVA will receive any beneficial returns on their purchase as the NTVA is exclusively meant to be utilized on the Intiva Health Platform. Investors and Purchasers should inform themselves of the legal requirements applicable to them with respect to the acquisition, holding, and disposition of the shares or tokens upon their delivery, and as to the income and other tax consequences to them of such acquisition, holding, and disposition.

The information contained in this White Paper was created by Intiva Health, majority owner of Intiva Token, Inc., from its own internal records and from published and unpublished sources it believes to be reliable. Neither this White Paper nor any supplementary data purports to be inclusive, and, accordingly, each prospective Investor and Purchaser is expected to conduct his/her/its own due diligence. Neither the Company nor any of its respective officers, directors, employees, affiliates, advisors, or agents make any representation or warranty, express or implied, as to the accuracy or completeness of this White Paper or any of its contents, and no legal liability is assumed or is to be implied against any of the aforementioned with respect hereto. No information contained in this White Paper or any other written or oral communications transmitted or made available to a recipient of this White Paper is, or shall be relied upon, as a promise or representation, whether as to the past or future, and no liability will attach. In addition, any projections and estimates contained in this White Paper involve numerous and significant subjective determinations. Accordingly, no representation or warranty can be made or is made as to the accuracy or attainability of such estimates and projections. The Company does not expect to update or otherwise revise this White Paper or any projections attached thereto. Such projections have been prepared by and are the sole responsibility of the Company and have not been reviewed or compiled by the Company's independent auditors. This White Paper does not constitute an offer to sell, or a solicitation of an offer to buy, Company Shares or NTVA in any jurisdiction in which it is unlawful to make such an offer or solicitation. Neither the United States Securities and Exchange Commission (SEC) nor any other federal, state, or foreign regulatory authority has approved the offering, this White Paper, the investment in the Company's shares, and/or the purchase of NTVA. Furthermore, the foregoing authorities have not confirmed the accuracy or determined the adequacy of this White Paper or the information contained herein, nor is it intended that the foregoing authorities will do so. Prospective Investors and Purchasers should make their own investigation and evaluation of the Company, including the merits and risks involved in an investment therein.

In particular, any potential Investor and Purchaser confirms that: (1) any discussions between representatives of the potential Investor or Purchaser and the Company and its affiliates regarding the acquisition of Company Shares or NTVA were initiated by one or more representatives of such potential Investor or Purchaser; and (2) prior to delivery of this White Paper or other offering of the Company's shares or NTVA, neither the Company, nor its respective affiliates, have made an interest in the Company available for purchase by such potential Investors or Purchasers, either as an offer that can be accepted by potential Investors or Purchasers or as an invitation extended to potential Investors or Purchasers to make an offer to subscribe for the investment.

Nothing in this White Paper is intended to create a contract for the investment in the Company, and each potential Investor and Purchaser acknowledges that the Company will rely on this assertion of a potential Investor or Purchaser's statements with respect to compliance with the laws of the jurisdiction in which the potential Investor or Purchaser is legally domiciled.



ORGANIZATION, BUSINESS, & PURPOSE

Organization & Current Operations

The Intiva Health Platform, developed by Intiva Health, is the first integrative career platform allowing licensed medical professionals, such as Doctors of Medicine (MD), Doctors of Osteopathic Medicine (DO), Doctors of Dental Surgery (DDS), Doctors of Podiatric Medicine (DPM), Doctors of Pharmacy (PharmD), Physician Assistants (PA), Nurse Practitioners (NP), Certified Registered Nurse Anesthetists (CRNA), Certified Nurse-Midwife (CNM), Clinical Nurse Specialist (CNS), Registered Nurse (RN), and more (collectively, “LMPs”), to manage every aspect of their career, such as credentials, licensure management, continuing education coursework, insurance, Health Insurance Portability and Accountability Act (HIPAA) compliant communication, and job opportunities. The Platform also enables LMPs to connect with facilities and medical groups, such as hospitals, medical groups, skilled nursing facilities, urgent care clinics, home health, and more (collectively, “FMGs”), in order to streamline recruitment efforts, expedite credentialing processes, and maintain compliance. This results in an unprecedented and seamless solution that relieves administrative burdens for both LMPs and FMGs. The Intiva Health Platform currently has thousands of LMP and FMG users.

The Intiva Health Platform offers a suite of solutions that facilitate compliance and organization for LMPs and FMGs completely free. The Intiva Health Platform also provides Key Partners targeted access to LMPs and FMGs through the Intiva Marketplace, while protecting the identity of individuals and entities participating on the Platform (“Users”) by only allowing access through expressed consent. Key Partners include, but are not limited to, partners in pharmaceutical, continuing education, and professional liability companies. The Intiva Health Platform is comprised of the following subset of features:

ReadyDoc™ – LMPs can securely store, manage, and share all of their documents and medical credentials from one place, eliminating paperwork, and automating the critical task of staying compliant. Powered by DLT, ReadyDoc™ utilizes the most secure technology in the market. LMPs are alerted on expiring credentials so that they never miss a deadline and can share their credentials with trusted administrators to create a collaborative network of compliance. FMGs can manage multiple LMPs within their organization from a custom credentials dashboard.

Intiva Careers™ – A unique and disruptive career matching solution. LMPs can upload their resume and easily apply for opportunities. Careers supports an anonymous application process, with filters that go as far as searching by geolocation, board certification, and desired salary. LMPs can search over 9000+ clinical positions across the US, including locum tenens. FMGs can post jobs and find qualified candidates through CV Search and can keep track of applicants and manage job postings.

Continuing Education – Intiva Health partners with the top thought leaders to offer continuing medical education, including Accreditation Council for Continuing Medical Education, state required, board preparation, and Maintenance of Certification courses. LMPs can choose from a library of listings and once completed, the Platform will automatically store certifications. Over 80% of the courses are free.

Intiva Connect – Connect brings HIPAA-compliant messaging, emailing, and document sharing to LMPs. The Connect feature allows LMPs access and share patient records, submit lab orders, and connect with other LMPs on the Platform. Furthermore, Connect integrates with EHRs and lab applications across the US, making it a complete interoperability solution.

Marketplace – Vetted and relevant healthcare products and services available for Users to purchase with NTVA, such as: medical malpractice insurance, cyber risk insurance, medical device, and more.

iGO HD™ – streaming service for interactive, on-demand content pertaining to CME courses and webinars, training, product, news and promotional material. This service was originally designed for fan websites (e.g. music, sports, etc.) to provide a unique interactive experience and fan engagement. It was most notably used by the Backstreet Boys 20th Anniversary Celebration.

The Intiva Health Platform is an innovative all-in-one solution for healthcare professionals who historically, have had no choice but to use disparate and outdated systems.

With several decades of collective healthcare expertise, the Intiva Health Platform focuses on volume, velocity, and veracity of healthcare data by capturing four and a half (4.5) to five (5) times more unique data points than its competitors. Given the Platform’s wealth of data points and services, the Company has access to fifteen (15) monetization avenues, discussed in the section entitled “Business Model” below which creates a diversified business model that no other solution in the market currently replicates.

Business Model

Intiva Health holds agreements with several key healthcare industry partners to bring critical tools and resources to LMPs across the United States.³ These Key Partners, among others, include professional liability companies such as Arthur J. Gallagher (AJG), Cooperative of American Physicians (CAP), and continuing education content providers such as Advancing Knowledge in Healthcare (AKH), Perinatal Resources (PRI), and the National Osteoporosis Foundation (NOF) (collectively, “Key Partners”). Intiva Health partners are currently able to take advantage of the Platform to interact with LMPs through the following monetization avenues:

³ Intiva Token, Inc., as a subsidiary of Intiva Health, also benefits from these partnerships.

- A. Sponsored Alerts.** Key Partners have access to a rotation of alerts that notify the LMP of document expirations. There are expiration events in a given year that create a robust inventory of sponsorship opportunities for Key Partners. These alerts, delivered via text message (SMS), email, and push notification, are received on each of the following number of days prior to the date of a document's expiration: 120, 90, 60, 45, 30, 15, 10, 7, 5, 3, 1, and 0. For example, a professional liability partner will have several opportunities to sponsor alerts on insurance-related documents that are due to expire, such as medical malpractice, property and casualty, cyber risk, and life insurance.
- B. Referrals.** At the expressed consent of any LMP, Intiva Health can provide qualified leads to Key Partners. LMPs can indicate to Intiva Health that they are interested in a particular product or service offered in the Marketplace. Intiva Health facilitates the referrals by providing all of the necessary information for a key partner to provide services to the consenting LMP. For example, a LMP can express that he or she is interested in hearing about employment opportunities from FMGs, which then automatically initiates the transfer of pertinent metadata for the FMG to connect with the LMP.
- C. Grants.** As a distributor of accredited continuing education content, Intiva Health is eligible to receive a portion of the grant allocated for distribution of online content by accredited continuing education content providers. Intiva Health offers this content to LMPs nationwide, and therefore continues to demonstrate increased viewership for key continuing education content providers.
- D. Sales.** Intiva Health collects up to fifty percent (50%) of fees on all products and services sold through the Intiva Health Marketplace. For example, professional liability companies and brokers are willing to pay a percentage fee for the amount of insurance written and sold. A study conducted by a malpractice carrier concluded that the average medical malpractice policy across several physician specialties equates to over fifty-four thousand USD (\$54,000) per year.⁴ The average commission on each policy ranges between twenty percent and thirty percent (20%–30%). The Company receives between thirty percent and seventy percent (30%–70%) of this commission per medical malpractice policy written.


4 How Much Does Medical Malpractice Insurance Cost?, Gallagher Healthcare (Dec. 12, 2017), <https://www.gallaghermalpractice.com/blog/post/how-much-does-medical-malpractice-insurance-cost>.

The Company can market in traditional ways, but also has the ability to pinpoint what medical professionals need at specific times. This allows for the following advantages:

Verified access to qualified leads that coincide with the time of need (within 120 days)

Verified access to qualified leads that coincide with the event of need (i.e., a malpractice document set to expire)

Alerts and referrals that are requested by the LMP in advance (opt-in)



The lifetime value of each deal may be in the hundreds of thousands of dollars, which emphasizes the importance of Intiva Health's proximity to the User's professional data and efficiency in reaching the User at the exact right time.

Additional monetization avenues available on the Intiva Health Platform include, but are not limited to, livestream continuing medical education, Curriculum Vitae (CV) search, ReadyDoc™(API), job posting, expert finding, promotional video channels (iGo HD™), medical opinions, honoraria match, sentiment analysis, fee income research opportunities, cyber liability coverage, and orders via Intiva Connect (labs, tests, x-rays).

Strategic Plan & Distributed Ledger Implementation

Based on the existing customer base, data set, and product line, the Company is uniquely positioned to be the industry leaders in healthcare data and career management platforms in what is projected to become the largest employment sector in the United States in 2022.⁵

As the Company looks forward, the organization has recognized an opportunity to address significant issues with existing practices, particularly in LMP credentialing. Existing practices, detailed in the section entitled “Current State of Credentialing Process” below, are often entirely analog, inefficient, and wasteful. It is not uncommon for a LMP to wait several weeks to months to be granted privileges to practice with a FMG, which results in billions of dollars in financial loss, many wasted hours, and a material decrease in the quality of healthcare for patients.

Credentialing software helps, but falls critically short because of its centralized pay-to-play business model. This kind of software suffers from the following flaws:

- Delays due to inefficiency – often requiring weeks to months to collect data;

- Reliability – the software is prone to errors and irregularities;

- Presence of Intermediaries – each with a different interpretation of facts provided;

- Lack of security – data is centralized and often transferred through non-secured channels; and

- Ownership of LMP data – entities own LMP data and information rather than the LMPs themselves.

Intiva Health is focused on addressing these breakdowns by utilizing DLT to conduct LMP credentialing processes. Applying this technology removes the pay-to-play nature of the existing process and gives facilities quicker access to information necessary to make a decision on LMP practice privileges. Furthermore, DLT provides the following advantages:

- LMP will have an immutable repository of all of his or her credentials;

- Time-stamped, hashed credentials will provide unparalleled security, eliminating the risk of tampering or falsification;

- Transactions within a distributed ledger will mitigate the risk of unsecured transfers of sensitive data;

⁵ Richard Henderson, Industry employment and output projections to 2022, Monthly Labor Review, U.S. Bureau of Labor Statistics (Dec. 2013), <https://doi.org/10.21916/mlr.2013.39>.

LMPs and FMGs will be able to access data for free;

Records will be considered irrefutable and become easily searchable; and

Data accuracy would be improved and ensured because all parties have an interest in the upkeep of said data.

Existing DLTs, like blockchain, may serve the aforementioned goals, but there are concerns about transaction speeds, data storage, and fairness. Accordingly, Intiva Health has partnered with Swirlds, Inc. (“Swirlds”), the creator of Hashgraph technology, a revolutionary improvement in the DLT space.

Hashgraph

As Dr. Leemon Baird describes in *Overview of Swirlds Hashgraph*, “the Hashgraph data structure and Swirlds consensus algorithm provide a new platform for distributed consensus.”⁶ Hashgraph offers a number of technological benefits over traditional blockchain technology. Due to material data structuring differences, Hashgraph ensures that no individual can manipulate the order of transactions; no individual can stop or delay a transaction; and transaction speeds are significantly faster. Hashgraph is Asynchronous Byzantine Fault Tolerant and Atomicity, Consistency, Isolation, Durability (ACID) compliant.

Intiva Health is thrilled to be one of the few companies awarded a direct partnership with Swirlds to develop a Hashgraph-based platform. The Company is currently integrating Hashgraph technology and is expected to be the first market application to utilize Hashgraph technology.

Fragmentation

Before documents are written onto the Hashgraph-powered ledger, documents will be encrypted and broken into fragments for storage across the node network. Fragmentation refers to the process of splitting a file into a number of pieces before distribution. Fragmentation creates additional layers of security and privacy for every document in the system, and ensures that in the unlikely event that a node is compromised not a single document will be exposed.

Note: This is further depicted in Addendum C.

6 Leemon Baird, *Overview of Swirlds Hashgraph* (May 31 2016), available at <http://www.swirlds.com/downloads/Overview-of-Swirlds-Hashgraph.pdf>.

Intiva Token (NTVA)


The Company is issuing a token called Intiva Token (“NTVA”). NTVA has been built to embody the principles of cryptocurrency, and pledges to bring a meaningful and operational product to the table, while offering a fair allocation of tokens.

NTVA is the first to serve LMPs by offering incentives to participate in the Intiva Health Platform. Each time a User action is taken, there is a token reward for the action. As a result, NTVA will be owned directly by Users of the Intiva Health Platform.

The Intiva Health Platform is the first publicly available Hashgraph-based platform to incorporate a tokenized economy. The sole purpose of NTVA is to be used within the Intiva Health Platform. NTVA can be used to purchase goods and services on the Intiva Health Platform, such as continuing medical education (CME) courses, malpractice insurance, medical devices, and medical equipment. NTVA also enable Users to unlock special benefits, like discounts and promotions from Key Partners. Furthermore, NTVA add value to the Platform by providing a digital trail of transactions.

Beyond use for LMP-oriented services on the Intiva Health Platform, the Company is making arrangements with several foundations and charities that will accept the transfer of NTVA as an official donation method. Among these charities are partners like the National Osteoporosis Foundation. Foundations and charitable organizations may use NTVA on the Intiva Health Platform to purchase advertisements, recruit LMPs, promote CME courses, and drive membership.

NTVA is not intended for use as a speculative investment instrument.



EMERGING TECHNOLOGY

The Intiva Health Platform currently allows thousands of LMPs to manage all aspects of their career and enables FMGs to streamline recruitment and credential verification efforts. The integration of Hashgraph technology into the existing platform revolutionizes the current credentialing process, providing many benefits to Platform Users, like security, speed, and trust. This emerging feature is called ReadyDoc™.

Current State of Credentialing Process

Currently, the verification process of an LMP’s credentials is as follows:

1 Medical providers submit credential documents to hospitals	2 Hospitals begin the verification process via phone, Internet, mail, and fax	3 Verification process is repeated for each document	4 Documents are submitted to medical staff committee for approval of privileges
--	---	--	---

The existing process is prone to human error, may take several weeks to months, and is dependent on centralized and corruptible storage. Furthermore, documents can be altered, lost, and forged, resulting in an unreliable system to verify the credentials and reputation of a medical provider.

The ReadyDoc™ feature offers a significant improvement to the current credentialing and verification process. By integrating Hashgraph distributed ledger technology, the credentialing and verification process is reduced to two-steps: (1) LMPs submit verified, hashed medical credentials to hospitals via the Intiva Health Platform; and (2) documents are submitted directly for approval of privileges to medical staff committees. The Intiva Health Platform handles this process from start to finish, providing instantaneous verification.

1 LMPs submit verified hashed credentials to hospitals via the Intiva Health Platform	2 Documents are submitted to medical staff committees for approval of privileges
---	--

LMPs are required to go through an arduous credentialing process each and every time they move to a new medical facility. The credentialing process consists of reviewing a substantial amount of documentation while verifying authenticity with the source issuer as part of the approval to participate in the functions of a healthcare network. The number of documents in a credentialing package vary based on several factors, but range anywhere from fifteen (15) to forty (40) documents. Successful credentialing of a provider can take anywhere from six (6) weeks to four (4) months to accomplish. LMPs are likely to change facilities every one (1) to three (3) years, and their careers can last over forty (40) years, creating a need for a solution that is technologically up-to-date to meet the needs of the healthcare industry.

ReadyDoc™

As previously described in the section entitled “Current State of Credentialing Process,” current provider credentialing is a process that is inefficient, complex, ongoing, and involves tedious and unsustainable workflows.

ReadyDoc™ is a solution that disrupts the current processes of credentialing and primary source verification by storing documents and credentials in a distributed ledger that is only permissible to necessary participants in the credentialing process. LMPs and FMGs benefit from ReadyDoc™ by obtaining information that is pre-verified, securely stored, and readily available. This creates an ongoing and self-auditing verification of provider work history and clinical reputation.

ReadyDoc™ works fluidly between FMGs across the United States, allowing these organizations to instantly verify work history and clinical reputations. Qualified locum tenens LMPs can cover for sick leave and staff emergencies immediately. LMPs can efficiently respond to public health emergencies, as organizations vet first responders’ credentials instantly. ReadyDoc™ eliminates redundancy and the need for third-party verification organizations, allowing FMGs to focus solely on the clinical reputation of the LMPs and hiring them in a timely manner.

Furthermore, the application of a decentralized and continuous credential verification system can help provide quality care to areas impacted during a natural disaster or a mass casualty incident. Circumstances such as these, require FMGs and governmental organizations to quickly find qualified medical staff. ReadyDoc™ speeds up and improves this process to ensure that the LMPs responding to the event are qualified to do so. And finally, ReadyDoc™ is available everywhere.

LMPs and FMGs utilize ReadyDoc™ to input and manage provider data. There are between fifteen (15) and forty (40) documents in a credential file. ReadyDoc™ allows LMPs and FMGs to manage the following credentials:

- 1. State Medical License**

Medical license for the state in which they practice.

Critical/Required Data Points:

Medical licenses in the state where the facility is located

2. Medical School Documentation

Licensed physicians must have gone through a recognized medical school.

Critical/Required Data Points:

Physician's medical school education
Documented graduation dates

3. Postgraduate Training

Commonly referred to as residency and fellowship programs.

Critical/ Required Data Points:

Documentation of all postgraduate training

4. Board Certifications

Additional training physicians may obtain in any specific discipline.

Critical/Required Data Points:

Documentation must be provided if required by facility

5. Applications

Practitioners requesting to be members of the medical staff must complete an initial application provided by the facility.

Critical/Required Data Points:

Initial Application
Reappointment application (shorter version of initial)
Liability Questionnaire
Authorization to Release Information

6. Drug Enforcement Administration (DEA) Registration

DEA registration enables physicians to write prescriptions for controlled substances and medications.

Critical/Required Data Points:

Documentation of DEA registration must be on file

7. Life Support Certification

The three (3) most common life support certifications are BLS (Basic Life Support), ACLS (Advanced Cardiovascular Life Support), and PALS (Pediatric Advanced Life Support).

Critical/ Required Data Points:

Proof of documentation must be provided if required by the facility

8. Malpractice Insurance

Malpractice insurance coverage must be provided by each medical staff member.

Critical/Required Data Points:

Documentation of malpractice must be provided

9. Sanctions Checks

Verifying past history of fraud and abuse or malpractice history.

Critical/Required Data Points:

National Practitioner Data Bank (NPDB) query
Office of Inspector General (OIG) query
Medical malpractice claims history

10. Hospital/Surgery Center Privileges

Where applicable, practicing physicians may have hospital privileges granted at each facility.

Critical/Required Data Points:

Documentation of hospital or surgery center privileges must be provided at each location

11. Peer References

Peers who provide a reference need to be familiar with the individual's performance before making the reference.

Critical/Required Data Points:

A specific number of peer references, three to seven (3-7), that vary by FMG, must be documented prior to initial appointment

12. Curriculum Vitae (CV)

Curriculum Vitae listing their education, skills, experience, awards, and any other applicable information.

Critical/Required Data Points:

CV must be provided for the credentialing file

13. Government-Issued Photo Identification (ID)

Government-issued photo ID, such as a license or passport.

Critical/Required Data Points:

Color copy of a valid ID must be provided

14. Health Documents

Varying by FMG, there are four (4) primary health documents should be provided per facility requirements and are considered protected health information (PHI).

Critical/Required Data Points:

Flu Vaccine
History and Physical Exam
Hepatitis B vaccination
Tuberculosis clearance

15. Fluoroscopy Certification

Fluoroscopy certification is required by physicians who use the fluoroscopy machine.

Critical/Required Data Points:

Documentation of fluoroscopy certification as required by state

Other Miscellaneous Credentialing Documentation

- | | |
|--|---|
| <ul style="list-style-type: none"> • Emergency coverage credentials • Permanent resident card • Social security (SS) documentation • INS Visa • W-9 Form • Continuing Medical Education • Release of Information • Health Statement • References • Pediatric Advanced Life Support • Preceptorship/Hands-on Training • Drug Screening Results • PPD Skin Test Form (TB Screen) • Influenza Vaccine Consent Form • Time Sheets • Case Logs • Immunization Record • Disciplinary Records • State Medical Board Profile • Background Check • Authorized Release of Information • Background Check Report • VHA 10-285 • Titers • Health Attestation • Immunization Declination • Faculty Addendum • HIPAA Self-Verification Attestation • Skills Checklist • Federal Self-Certification • United States Office of Personnel Management Optional Forms • Certificate of Employment | <ul style="list-style-type: none"> • CMS National Plan and Provider Enumeration System • Educational Commission for Foreign Medical Graduates • Certificate of Liability Insurance • Appointment for Staff and Privileges • Emergency Management Plan Role • Core Privileges • Physician Appointment Application • Checklist • Facilitate CME Log • System for Award Management • Closing Report • Education Verification • Sex Offenders Record Search • Registered Nurse (RN) Profile Verification • TB Mask Fit • Excluded Parties List System • Occupational Safety and Health Administration (OSHA) Certificate • Chest X-ray • Physical Exam • I-9 Form • Transcript • Radioactive Material License • Affidavit of Good Moral Character • Child Protection Report • Adult Abuse Registry • Department of Veteran Affairs Service Center (VSC) Fingerprinting • VSC Sector Request • VSC Sector Packet |
|--|---|

For further insight on current and future developments to the Intiva Health Platform, reference Addendum D.

MARKET

Licensed Medical Professionals

LMPs spend over twenty-one percent (21%) of their time working on non-clinical paperwork,⁷ forfeiting countless hours of billable time. Additionally, both LMPs and FMGs risk potential practice-ending lawsuits and sanctions by using archaic and disorganized methods to track and manage LMP credentials, such as licenses, professional liability, and certifications. Similarly, healthcare industry players, such as pharmaceutical, continuing education, and professional liability companies, like Intiva Health's Key Partners, struggle to acquire accurate and verified LMP data, thereby wasting enormous amounts of their budget on ineffective and costly advertising and business development tactics.

Perhaps most importantly, these credentials are held by a few central bodies which censor, curate, and control this important information with little to no capability to share the information across a secure network, resulting in redundancies and information silos.

Cryptocurrencies, Tokens, & DLT

The cryptocurrency market has experienced tremendous growth in recent years which has led to a leap forward in ledger transparency and accuracy in digital products. This growth is driven by improved ease of access, media attention, globalization, and distrust of centralized institutions.

Cryptocurrency and DLT have promoted unprecedented innovation across various industries, such as financial, political, legal, supply chain, agriculture, identity and data protection, decentralized business applications, and now healthcare.

Intiva Health is capitalizing on all of the benefits that these technologies provide. Every INTVA transaction will be recorded, or "reinforced," giving a transparent digital transaction trail of some of the highest paid individuals across all industries, providing even further insights into the healthcare industry.

7 2016 Survey of America's Physicians: Practice Patterns.

ISSUANCE PLANS, TERMS & PARTICIPATION

The Company will use NTVA to tokenize the Intiva Health Platform and create a token economy on its platform. A token economy provides the ability to encourage engagement and reinforce desired behaviors on the Platform. These reinforcers are symbols, or tokens, that can be exchanged for other pieces of information. In other words, as NTVA are utilized or transferred on the Intiva Health Platform, these actions help trace transactions and essentially provide a digital trail of the actions for which the token was utilized.

The Intiva Health Platform offers LMPs an all-inclusive, one-stop, highly-secured place to manage and control their careers, while also leveraging help from FMGs and offering a non-intrusive venue for companies to offer their services and products to LMPs.

Specifically, LMPs, FMGs, and Key Partners will receive NTVA as rewards for engaging in or participating on the Intiva Health Platform. There are twenty-nine (29) activities that provide the opportunity to earn NTVA, these activities are also referred to as “Token Events.”

Key Partners can utilize NTVA for services on the Intiva Health Platform. For example, these partners and companies are encouraged to purchase advertisements on the Intiva Health Platform or search for and recruit LMPs.

NTVA are of fixed supply and will be made available to shareholders of the Company during a private sale of April 19, 2018 to April 26, 2018 (the “Share Private Sale”), presale period of April 30, 2018 to May 6, 2018 (the “Company’s Share Presale”) and during a sale period of May 7, 2018 to June 3, 2018 (the “Company’s Share Sale”) as a shareholder benefit. The Company seeks twelve million USD (\$12,000,000) in new equity investment during the Company’s Share Presale and Sale in the United States. Investors can invest in Company Shares at the price indicated in the chart included in the section entitled “The Company’s Share Offering, and such Investors will receive complementary NTVA as a shareholder benefit. The complementary NTVA will be distributed to Investors within thirty (30) days of the close of the Company’s Share Sale.

There is a fixed amount of one billion (1,000,000,000) NTVA. No additional NTVA will be created after these one billion NTVA are distributed. Non-U.S. persons can purchase NTVA during the NTVA Private Sale, Presale, and Sale in jurisdictions outside of the United States at fifty cents USD (\$0.50) per NTVA. The Company seeks to raise a minimum of twelve million USD (\$12,000,000) in the NTVA Pre-Sale and Sale. Tokens are not available for sale, directly or indirectly, to any U.S. Persons.

Additionally, NTVA may be earned by engaging in activity on the Intiva Health Platform, in the manner depicted in Addendum F of this White Paper.

LMP Distribution

LMPs can earn NTVA for participation on the Intiva Health Platform. The Company estimates this distribution to take place over three (3) to five (5) years. Currently, there are twenty-nine (29) actions on the Intiva Health Platform for which NTVA can be earned. These actions range from claiming an account to purchasing services on the Intiva Health Platform. Essentially, by participating on the Intiva Health Platform through these actions, the LMP “mines” NTVA for his or her own use.

For certain purchases made with NTVA, half a percent to two percent (0.5%-2%) of the NTVA used will be frozen for up to five (5) years. After the five (5) year freeze period, these NTVA will be redistributed to LMPs as a continuance of incentive rewards. This will enable the Company to continue to reward latecomers to the Intiva Health Platform, in the event that the original allocation for LMPs is fully distributed. This process is depicted in Addendum F of this document.

FMG Distribution

Distribution of NTVA to FMGs is based upon both FMG participation on the Intiva Health Platform, and direct purchase of NTVA by FMGs who are non-U.S. Persons located outside of the United States. Twenty percent (20%) of NTVA available to FMGs will be distributed to them as rewards for participation on the Intiva Health Platform. The Company estimates NTVA will be mined by LMPs, FMGs, and Key Partners over a three (3) to five (5) year period.

Distribution of NTVA

Allocation	# of Tokens	Percentage
Shareholder Benefit Offered to Investors in Intiva Token, Inc.	120,000,000	12%
Tokens Offered in the Intiva Token Sale to Purchasers ⁸	120,000,000	12%
Available for LMPs to Earn on Platform	350,000,000	35%
Available for FMGs to Earn/Buy on Platform ⁹	300,000,000	30%
Treasury/Reserves	55,000,000	5.5%
Miscellaneous	30,000,000	3%
Staff Incentives	25,000,000	2.5%
Total	1,000,000,000	100%

⁸ “Purchasers” are non-U.S. Persons located outside of the United States.

⁹ Only FMGs who are considered non-U.S. Persons and reside outside of the United States may purchase NTVA.

The Company's Share Offering

The Offering of Company Shares in the United States is being made pursuant to Rule 506(c) of Regulation D of the Securities Act of 1933, as amended ("the Securities Act"). Participation in the Offering is limited to "Accredited Investors" (as defined under the Securities Act, Rule 506 of Regulation D).

The Company will issue and provide an Offering Memorandum that will be prepared solely for use by prospective Investors in the Company. The Offering Memorandum will be prepared in connection with a private offering to Accredited Investors in the United States, individuals who will be required to verify their Accredited Investor status through a questionnaire and other necessary documentation. Non-U.S. Purchasers residing outside of the U.S. will be required to provide personally identifiable information (PII) in order to comply with Know Your Customer (KYC) and Anti-Money Laundering (AML) requirements.

Investors can invest in Company Shares at the price indicated in the chart below per Company Share, and such Investors will receive complementary NTVA as a shareholder benefit.

From	To	Price/Share	Tokens Received
1,000	2,000	\$ 1.00	2,500
2,001	4,000	\$ 0.99	6,050
4,001	10,000	\$ 0.98	14,075
10,001	20,000	\$ 0.97	30,200
20,001	30,000	\$ 0.96	50,400
30,001	40,000	\$ 0.95	70,700
40,001	50,000	\$ 0.94	91,100
50,001	60,000	\$ 0.93	111,600
60,001	70,000	\$ 0.92	132,100
70,001	80,000	\$ 0.91	152,750
80,001	90,000	\$ 0.90	173,500
90,001	100,000	\$ 0.89	194,300
100,001	110,000	\$ 0.88	215,175
110,001	120,000	\$ 0.87	236,150
120,001	130,000	\$ 0.86	257,200
130,001	140,000	\$ 0.85	278,350
140,001	150,000	\$ 0.84	300,000
150,001	160,000	\$ 0.83	321,000
160,001	170,000	\$ 0.82	342,000
170,001	180,000	\$ 0.81	365,000
180,001	190,000	\$ 0.80	385,450
190,001	200,000	\$ 0.79	407,100

The Intiva Token Offering

Non-U.S. Persons can purchase NTVA during the NTVA Private Sale, Presale, and Sale in jurisdictions outside of the United States. NTVA are not available for sale, directly or indirectly, to any U.S. Persons. NTVA are not securities and, therefore, do not confer any rights. Rather, NTVA are utility tokens that are only intended for use on the Intiva Health Platform. NTVA will be sold at \$0.50 per token.

Discounts:

Both the Company's Share Offering and Intiva Token Offering will subscribe to the below discount schedule.

Week	From	To	Discount
Private Sale	April 19	April 26	50%
Presale	April 30	May 6	30%
Stage 1	May 7	May 13	25%
Stage 2	May 14	May 20	20%
Stage 3	May 21	May 27	10%
Stage 4	May 28	June 3	0%

Total Tokens Created

There will be a total of one billion (1,000,000,000) Intiva Tokens created. The Company will not create any additional NTVA.

Treasury

The Company will maintain a treasury of NTVA for future needs, including, but not limited to, operations and marketing. The Company will use the reserved NTVA to market to Users on the Platform. NTVA will also be used to recruit and negotiate agreements with Key Partners and FMGs to use the Intiva Health platform.

Summary of the Share Offering

Share Offering:	Intiva Token, Inc. Shares are an investment in the Company. Investors who purchase Shares will hold equity in the Company and may have the rights to dividends at the sole discretion of the Company. Investors will not hold any other rights, including, but not limited to, voting rights.
Price Per Share (in USD):	See accompanied charts above.
Start of Private Sale:	April 19, 2018
End of Private Sale:	April 26, 2018
Start of Presale:	April 30, 2018
End of Presale:	May 6, 2018
Start of Sale:	May 7, 2018
End of Sale:	June 3, 2018
Currencies Accepted:	USD / BTC / ETH
Total Shares Authorized: Comprised of:	Two Hundred Million (200,000,000) One Hundred Ninety-Eight Million (198,000,000) Shares of Class B Common Shares, One Million (1,000,000) Shares of Class A Common Shares, and One Million (1,000,000) Shares of Preferred Shares
Amount to be Raised:	Twelve Million (\$12,000,000) USD
Investor Benefit:	NTVA will be distributed as a benefit to Investors.
Investors:	This Share Offering is limited to "Accredited Investors" pursuant to Rule 506(c) of Regulation D of the Securities Act.

Summary of the Intiva Token Offering

Token Offering:	NTVA may be used on the Intiva Health Platform to purchase items on the marketplace, unlock special benefits, and facilitate services for FMGs and Key Partners.
Price Per Token (in USD):	Fifty Cents USD (\$0.50)
Start of Private Sale:	April 19, 2018
End of Private Sale:	April 26, 2018
Start of Presale:	April 30, 2018
End of Presale:	May 6, 2018
Start of Sale:	May 7, 2018
End of Sale:	June 3, 2018
Currencies Accepted:	USD / BTC / ETH
Total Tokens Offered:	One Hundred Twenty Million (120,000,000) NTVA.
Total Tokens Created:	One Billion (1,000,000,000) NTVA. There will not be any additional NTVA created.
Amount to be Raised:	Twelve Million (\$12,000,000) USD
Purchasers:	<i>The purchase of NTVA is made only to Non-U.S. Purchasers outside of the United States, and only in jurisdictions in which such a token offering is not prohibited.</i>

Uses of Funds

The funds from the Offering will be used to provide funding for the following:

Capital and Expense	Estimated Allocation
Administrative Expenses	10%
Employee Incentives and Hiring	10%
Development	10%
Marketing	35%
Sales	15%
Reserves	20%

The allocation of the use of proceeds contained herein are estimates and subject to change without notice to Investors or Purchasers.

Technical Offering Mechanism

During the Offering, Investors and Purchasers will be asked for PII in order to participate in the Sale. The information is collected to ensure compliance with the various securities laws of the United States, as well as KYC and AML requirements. All U.S. Investors must satisfy the obligations promulgated under the Accredited Investor standard pursuant to Regulation D, Section 506(c) of the Securities Act.

Participation in the Intiva Token Offering

The Offering of NTVA is limited to non-U.S. Persons who reside outside of the United States in jurisdictions in which such an offering is permitted. NTVA are not offered for sale to any U.S. Persons, as defined in Rule 902 of the Securities Act. Purchasers of NTVA will be required to provide PII in order to ensure compliance with KYC and AML laws. NTVA are intended to be used only on the Intiva Health Platform and are not intended to be sold on any secondary markets or exchanges.

NTVA will be offered for purchase during a private sale from April 19, 2018 to April 26, 2018 (the “NTVA Private Sale”), presale period from April 30, 2018 to May 6, 2018 (the “NTVA Presale”), and a sale period from May 7, 2018 to June 3, 2018 (the “NTVA Sale”).

Prospective Purchasers can purchase NTVA on the Company's website. Purchasers shall purchase NTVA by wire transfer or by using a debit or credit card in the amount of the purchase. NTVA will be transferred to the Purchaser through a digital wallet within thirty (30) days from the close of the Sale. NTVA are not securities and, therefore, they do not confer any rights. Rather, NTVA are utility tokens that are only intended for use on the Intiva Health Platform.

Participation in the Company's Share Offering

Prospective Investors in the United States can purchase Company Shares by following instructions provided at <https://token.intivahealth.com>.

The Offering of Company Shares in the United States is limited solely to Accredited Investors, as defined in Regulation D under the Securities Act, meaning only those persons or entities coming within any one or more of the following categories:

- (i) Any bank, as defined in Section 3(a)(2) of the Securities Act, or any savings and loan association or other institution defined in Section 3(a)(5)(A) of the Securities Act, whether acting in its individual or fiduciary capacity; any broker-dealer registered pursuant to Section 15 of the Exchange Act; any insurance company, as defined in Section 2(13) of the Securities Act; any investment company registered under the Investment Company Act of 1940 or a business development company, as defined in Section 2(a)(48) of that Act; any Small Business Investment Company licensed by the United States Small Business Administration under Section 301(c) or (d) of the Small Business Investment Act of 1958; any plan established and maintained by a state, its political subdivisions or any agency or instrumentality of a state or its political subdivisions for the benefit of its employees, if such plan has total assets in excess of five million USD (\$5,000,000); and any employee benefit plan within the meaning of the Employee Retirement Income Security Act of 1974, if the investment decision is made by a plan fiduciary, as defined in Section 3(21) of such Act, that is either a bank, savings and loan association, insurance company or registered investment advisor, if the employee benefit plan has total assets in excess of five million USD (\$5,000,000) or, if a self-directed plan, with investment decisions made solely by person(s) that are Accredited Investor(s);
- (ii) Any private business development company, as defined in Section 202(a)(22) of the Investment Advisers Act of 1940;
- (iii) Any organization described in Section 501(c)(3) of the Internal Revenue Code of 1986, as amended (the "Code"), any corporation, Massachusetts or similar business trust, or company, not formed for the specific purpose of acquiring the Common Stock, with total assets in excess of five million USD (\$5,000,000);

- (iv) Any director or executive officer of the Company;
- (v) Any natural person whose individual net worth, or joint net worth with that person's spouse, exclusive of the value of the person's primary residence net of any mortgage debt and other liens, at the time of his or her purchase exceeds one million USD (\$1,000,000);
- (vi) Any natural person who had an individual income in excess of two hundred thousand USD (\$200,000), or joint income with that person's spouse in excess of three hundred thousand USD (\$300,000), in each of the two (2) most recent years and who reasonably expects to reach the same income level in the current year;
- (vii) Any trust with total assets in excess of five million USD (\$5,000,000), not formed for the specific purpose of acquiring the Common Stock, whose purchase is directed by a sophisticated person as described in Rule 506(b)(2)(ii) of Regulation D; or
- (viii) Any entity all of whose equity owners are Accredited Investors.

The term "net worth" means the excess of total assets over total liabilities, exclusive of the value of the investor's primary residence net of any mortgage debt and other liens. In determining income, the investor should add to his/her/its adjusted gross income any amounts attributable to tax-exempt income received, losses claimed as a limited partner in any limited partnership, deductions claimed for depreciation, contributions to an IRA or Keogh retirement plan, alimony payments, and any amount by which income from long-term capital gains had been reduced in arriving at adjusted gross income.

Investors will be required to represent to the Company in writing that he/she/it is an Accredited Investor under Regulation D, as described above, and may also be required to provide certain documentation in support of such representation. In addition to the foregoing requirement, the investor must also represent in writing that he/she/it is investing in the Company for their own account, not for the account of others, and not with a view to resell or distribute such securities. For U.S. Accredited Investors, they must satisfy the obligations promulgated under the "Accredited Investor" standard pursuant to Regulation D of the Securities Act. This can be satisfied by completing the accreditation process in one of three general manners:

- i. Accreditation based on Investor's Income:
 - Investor to provide
 - (a) Internal Revenue Service (IRS) forms that report the Investor's income for the past two (2) years; and
 - (b) Written representation that he/she has a reasonable expectation of reaching the income level required to qualify as an Accredited Investor in the current year.

- ii. Accreditation based on Investor's Net Assets: Investor to provide
 - (a) Documents dated within the past three (3) months, including bank statements, brokerage statements, and tax assessments (to confirm assets), and a report from one of the national consumer reporting agencies (to confirm liabilities); and
 - (b) Written representation that the Investor has disclosed all liabilities necessary to make a net worth determination.

- iii. Third-Party Verification Letter: Investor to provide a written confirmation ("Third-Party Verification Letter") from a broker-dealer, a registered investment advisor, a licensed attorney, or a Certified Public Accountant (CPA) confirming that such person has taken reasonable steps to verify that the Investor qualifies as an Accredited Investor, as defined in Rule 501(a) of Regulation D of the Securities Act, as amended.

Once the accreditation information is verified, and the KYC and AML verification is complete, the Investor will need to confirm the investment and initiate payment. To finalize the transaction, all Investors will be required to sign a Subscription Agreement. A subscription will not be considered "accepted" until the Investor receives a duly executed copy of the Subscription Agreement from the Company. Prior to acceptance, the Company reserves the right to refuse, at its sole discretion, a subscription from any prospective Investor and/or request additional information or documentation to verify an Investor's eligibility for this Offering.

If individuals are interested in participating in the Company's Share Sale, they may do so by following instructions provided at <https://token.intivahealth.com>.

Post-Offering Securities Compliance and Transfer Restrictions

The issuance and sale of Company Shares have not been registered under the Securities Act or any other applicable securities law and, unless so registered, the Company Shares may not be offered, sold, pledged, or otherwise transferred, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities law.

Each Investor in Company Shares will be deemed to represent, warrant, and agree as follows:

- (i) He/she/it is an Accredited Investor (as defined in Rule 501 of Regulation D under the Securities Act) or a qualified investor in his/her/its applicable jurisdiction;

- (ii) If he/she/it is a U.S. Person, he/she/it acknowledges that unless the Company Shares are registered with the Securities and Exchange Commission, they will not be permitted to offer, sell, or transfer Company Shares until the Lock-up Period lapses, which is one (1) year from the date of purchase; and after such Lock-up Period, he/she/it will be permitted to sell or otherwise transfer Company Shares subject to applicable law; and
- (iii) and He/she/it acknowledges that Company Shares will not be required to accept for registration of transfer any Company Shares acquired by it, except upon presentation of evidence satisfactory to the Company that the restrictions set forth herein and in the Offering Memorandum have been complied with.

Reporting and Transparency for Investors

The Company intends to issue progress reports to its investors on a quarterly and annual basis. Such progress reports will detail the business practices and actions over the past year and provide a basic overview of how the organization functions. The reports will include known risk factors, data on the performance of the Intiva Health Platform or systems and services, and statistics on the Company's Shares. Investors may also request progress reports in writing and subject to the requirements of the Bylaws and other applicable corporate documents.

The Risk Factors

Investing in the Company involves a high degree of risk, and, therefore, should be undertaken only by investors capable of evaluating the risks of an investment and bearing the risks of a complete loss of all invested capital. Prospective Investors and Purchasers should carefully consider the risks described below and in the Offering Memorandum, and the risk with respect to the Company. Investors and Purchasers shall also consult with their professional advisors before deciding whether to invest or purchase. There is no guarantee that Investors or Purchasers will receive a return of their capital or any returns on their investment. An investment in the Company is designed only for sophisticated persons who are able to risk losing their entire investment in the Company. The risks described below are not exhaustive.

Business and Strategic Risk

The Company is subject to changes in the economic conditions in the broader global marketplace. In the event of an economic downturn, the Company's business plan, ability to generate revenue, and overall solvency may be at risk. Companies operating in the blockchain and cryptocurrency industry, in general, are highly risky, and the likelihood of failure of the business, regardless of the overall business climate, is possible.

Investment in the Company could result in a complete loss of investors' capital. Investing in the Company or NTVA may not be suitable for all Investors or Purchasers as it involves a high degree of risk. Investors and Purchasers may

lose their entire investment. Before deciding to invest, prospective Investors and Purchasers are advised to consult a professional advisor who specializes in advising on investments of the kind described in this White Paper. Prospective Investors and Purchasers should consider carefully whether investing in the Company or the NTVA is suitable for them in light of their personal circumstances and the financial resources available to them.

Risk of Investing

Financial Risk and Use of Proceeds

The Company is not required to devote any amount of its assets, and it may cease any other activities described herein in its absolute discretion. Any “Use of Proceeds” information presented herein represents the Company’s current intentions and is subject to change based on a number of factors, including the amount of funds raised, developments in blockchain technology and cryptocurrency, or other factors that are difficult to predict. The Company has absolute discretion regarding the use of the proceeds raised in this Offering and may use such proceeds for any purpose, whether or not addressed in this section, without notice to any Investors or Purchasers that it is changing its intended approach. There are no assurances that such determinations ultimately made by the Company, which relate to the specific allocation of the net proceeds, will permit the Company to achieve its business objectives. In the event that the Company’s plans change, its assumptions change, or prove to be inaccurate, or the proceeds of this Offering prove to be insufficient, it may be necessary or advisable to reallocate proceeds, or to use proceeds for other purposes. The timing of profit realization, if any, is highly uncertain.

Regulatory Risk and Changes in Law and Regulations

Withdrawal or amendment of regulatory authorizations with respect to all or part of the business carried on by the Company, or with respect to the fitness or propriety of one or more individuals to perform their current roles might require the Company to cease conducting a particular type of business or modify the manner in which it is conducted.

The failure by the Company to obtain prior regulatory authorization in a jurisdiction where it has operated or the refusal of a regulatory body to grant that authorization in a jurisdiction where it may wish to operate, could prevent the Company from maintaining or expanding its business. Further, changes to laws or regulations, including the enactment of new requirements in relating to regulatory authorization, advertising, the Internet, or online commerce (or change in the application or interpretation of existing regulations or laws by regulators or other authorities) in any jurisdiction in which the Company currently conducts business, might oblige the Company to cease conducting business, or modify the manner in which it conducts business in that jurisdiction. Such changes could also have a materially adverse effect on the Company’s business, financial condition, and operating results, and/or subject the Company or its directors or Users to additional taxation or civil, criminal, regulatory, or other action.

Although the Company maintains policies and procedures that it considers adequate to detect any risk of failure to comply with its obligations, there is a risk of non-compliance arising from, among other things, human error, unauthorized access, technological failure, and fraud. Any non-compliance with applicable laws or regulations in any jurisdiction would have a significant impact on how the Company conducts its business.

In the case of virtual currencies, state regulators have created new regulatory frameworks or have published guidance as to how existing regulatory frameworks apply to virtual currencies. The Company could be adversely affected depending on whether a given regulatory agency decides to exert authority over the blockchain and blockchain assets, as it could affect the potential use and fungibility of NTVA, which shareholders will receive as a benefit of their investment in the Company.

Limited Operating History and Availability of Information

The offering, when issued, will constitute an investment in a company with limited operating history. As a result, prospective Investors and Purchasers do not have access to the same types of information with respect to their proposed investment as would be available to Investors and Purchasers in a company with a history of operation. There are no assurances that the Company will ever operate profitably or that Investors will ever receive a return on their investment.

Expected Operating Losses and Uncertainty of Future Profitability

The Company is in the early stage of development and has had little operating history on which to base an evaluation of its business and prospects. The Company expects to continue to incur significant losses. The time required for the Company to become profitable is uncertain, and there is no assurance that the Company will achieve profitability on a sustained basis, if at all. In addition, as a result of the Company's lack of operating history as well as the recent emergence of the markets addressed by the Company, the Company has neither internal nor industry-based historical financial data for any significant period of time upon which to project revenues or base planned operating expenses. The Company expects that its results of operations may also fluctuate significantly in the future as a result of a variety of factors, including: the continued rate of growth; the rate of acceptance of the Company's services and technology; the introduction and acceptance of new, enhanced, or alternative services by the Company or by its competitors; the Company's ability to anticipate and effectively adapt to a developing market and to rapidly changing technologies; the Company's ability to attract, retain, and motivate qualified personnel; pricing changes by the Company or its competitors; specific economic conditions in the market; general economic conditions; and other factors.

Inability to Manage Growth

If the Company experiences rapid growth in its operations it will place a significant strain on its managerial, operational, and financial resources. In order

to expand, train, and manage its workforce, and in particular, its developers, sales, and business development staffs. There is no assurance that the Company will be able to do this.

Small Number of Customers

The Company expects its sales to initially be concentrated among a few customers. Because the Company will rely heavily on each customer as its initial source of revenue, the loss of any significant customer or any reduction in fees by a significant customer may have a material adverse effect on its revenues.

Industry Risk

The growth of the blockchain industry, in general, as well as the blockchain networks on which the Company relies, is subject to a high degree of uncertainty. A decline in the popularity or acceptance of the Bitcoin or Ethereum networks would adversely affect the Company's results of operations. Factors that affect the development of the cryptocurrency industry and blockchain networks include, but are not limited to:

- Worldwide growth in the adoption and use of Bitcoin, Ether, and other blockchain technologies

- Government and quasi-government regulation of Bitcoin, Ether, and other blockchain assets and their use, or restrictions on or regulation of access to, and operation of blockchain networks or similar systems

- The maintenance and development of the open-source software protocol of the Bitcoin or Ethereum networks

- The development and maintenance of Hashgraph technology

- Changes in consumer demographics and public tastes and preferences

- The availability and popularity of other forms or methods of buying and selling goods and services, and

- General economic conditions and the regulatory environment relating to cryptocurrencies

Unfavorable developments or characteristics of any of the above circumstances could adversely affect the Company's business, including the functionality and benefit of the NTVA.

Developing Market and Unproven Acceptance of the Company's Products and Services

The Company currently has a limited number of customers. The market for the Company's technology has only recently begun to develop, is rapidly evolving, and is characterized by a number of market entrants with potentially competitive services. If the market fails to continue to develop, develops more slowly than expected, becomes saturated with competitors, or if the Company's technology does not achieve or sustain acceptance by the marketplace for a number of potential reasons, the Company's business, results of operations, financial condition, and prospects would be materially adversely affected.

Technology Risk


Intellectual Property and Proprietary Rights Generally

The Company's success depends significantly upon its proprietary technology, including various intellectual property rights. Although the Company seeks to protect its proprietary technology and intellectual property rights through, among other avenues, U.S. copyright, trademark, and/or patent protection, there is no assurance that such intellectual property which may be obtained and/or the intellectual property applications which may be filed by the Company, are sufficient to protect its technology or that any intellectual property will not be held invalid, circumvented, or infringed by others. In addition, the Company relies to a significant extent on proprietary know-how. The Company cannot ensure that others will not independently develop superior know-how to that which it now considers proprietary. Litigation may be necessary to enforce intellectual property issued to the Company, to protect trade secrets or know-how owned by it, or to determine the enforceability, scope, and validity of the proprietary rights of others. Enforcing or defending the Company's rights is expensive, could cause a diversion of its resources, and may not prove successful. Any failure to enforce or protect the Company's rights could cause it to lose the ability to exclude others from using its technology to develop or sell competing products.

TEAM & ADVISORS

The Company is managed by its core team of executives and advisors with specific experience in healthcare, DLT, and cryptocurrency.

Management Team	Description
<p>Jim Comstock President and Director Major General, US Army (Retired)</p> 	<p>In January 2018, Retired Major General Jim Comstock joined as President of Intiva Health. Jim served thirty-seven (37) years in the Army, leading Special Forces groups, commanding a Supply and Service Battalion, and, most recently, serving as the Commanding General of the 311th COSCOM. In his civilian career, Jim has had over thirty-five (35) years of experience in insurance and investments. He served as the Managing Director Public with Institutional Liability Management Partners, Group and Pension Manager at Lincoln National Insurance Company, and CEO of First Fold, an organization to preserve the memory of fallen service members. Jim brings decades of operational expertise in both military and civilian settings and is an exceptional addition to the team.</p>
<p>Shawn Frasquillo Executive Vice President of Development and Support</p> 	<p>Shawn has over ten (10) years of experience in healthcare operations, from direct patient care to administration. He uses his multifaceted skill set to drive implementation and integration, as well as research and product development. He oversees all Intiva Health products ensuring delivery, service, and support. Shawn holds a Bachelor's degree in Health Information Management from Texas State University.</p>
<p>John Hartigan Executive Vice President of Strategic Development</p> 	<p>John is the Founder and President of Hartigan Industries Inc., specializing in product development, brand management, and B2B relationship opportunities and sales. As an experienced entrepreneur, John excels at and enjoys managing startup businesses, product growth cycles, and bringing innovative solutions to niche markets.</p>
<p>Garry McIntosh Chief Operating Officer and Executive Vice President of Operations</p> 	<p>Garry oversees the project management, financial planning, and administrative activities of the Company. He obtained a Masters in Business Administration (MBA) with an emphasis in Healthcare Administration, from Texas State University. He has over seven (7) years of experience managing licensed medical professionals in anesthesia, emergency medicine, and private practice settings, which provides a valuable and unique perspective to Intiva Health.</p>




Advisors	Description
<p>Peter Kirby Founder & Former CEO Factom Making the World's Systems Honest</p> 	<p>Peter Kirby, co-founder of Factom, is a seasoned entrepreneur. Peter has spent the past fifteen (15) years involved in numerous successful early-stage tech companies and possesses a deep knowledge of business development and community-based marketing in the technology sector. His ventures have ranged from neurological supplements and investment financing to commercial development and real estate. As a leader in the blockchain space and distributed ledger technology, Peter has led multi-million-dollar operations and was the driving force behind delivering major products to market. Peter earned his degree in biochemistry from Lehigh University in Bethlehem, Pennsylvania and later pursued his Masters in Business Administration (MBA) in Entrepreneurship from the Acton School of Business in Austin, Texas, where he graduated Summa Cum Laude.</p>
<p>Carl Buccellato Board of Directors for Ellie Mae</p> 	<p>Carl has served on the board of directors for Ellie Mae since December 1997. From May 2008 to February 2012, Carl served as chief executive officer and director of SavingStreet, LLC, an e-commerce company. Carl was a private investor and, from June 2000 to May 2002, he served as a consultant to Ultrastrip Technologies, currently known as Echosphere Technologies, an engineering, technology development, and manufacturing company. Carl was a co-founder of Homeowners Group, Inc., a real estate services company, and served as its president and chief executive officer from 1982 to 1996. Carl has served on multiple boards across various industries.</p>
<p>Steve Kerr Senior Advisor & CLO (Fmr.) for Goldman Sachs</p> 	<p>Steve is a former Sr. Advisor to Goldman Sachs, following a six (6) year term as a managing director and Goldman's Chief Learning Officer (CLO). Before joining Goldman, he was General Electric's (GE) CLO and Vice President of Corporate Leadership Development for seven (7) years, where he worked closely with Jack Welch and led GE's renowned leadership education center at Crotonville.</p> <p>Steve has also served on the business school faculties of The Ohio State University, the University of Michigan, and the University of Southern California, where he was dean of the faculty and director of the Ph.D. program. He has authored or co-authored six (6) books and more than eighty (80) journal articles.</p> <p>Steve is a member of the board of directors of Harvard Business Publishing, The Motley Fool, and the Miami Children's Hospital Foundation, and is on the advisory board of the University of Pennsylvania's program in learning leadership and the Forbes School of Business.</p>
<p>Alexander Candelario Advisor</p> 	<p>Alexander is a retired Marine Officer and former partner at a major accounting firm who understands the concept of service leadership and has an intricate understanding of financial processes. He advises all departments of Intiva Heath, including Marketing, Sales, Product Development, and Administration. Alexander holds an undergraduate degree in Accounting and a graduate degree in Business Administration (MBA) from Texas A&M University.</p>
<p>Andrew J. Chapin CEO, benjaCoin Author, Art of the ICO Advisor, Various Token Projects</p> 	<p>Andrew is the co-founder and CEO of BENJA, a merchandise advertisement platform and operator of the benjaCoin crypto-token. Through Chapin Labs, Andrew has advised several projects in blockchain and cryptocurrency, including ETHlend and BestMeta. Previously, Andrew coordinated revenue and growth for Feathr as the Vice President of Business Development and has also coordinated sales, marketing, and user acquisition efforts at Microsoft and Color Labs.</p>

CONTACT INFORMATION

Prior to the finalization of the Offering, the Company will provide to each prospective Investor and Purchasers, such Investor's and Purchaser's representatives and advisors, if any, the opportunity to ask questions and receive answers concerning the terms and conditions of this Offering, and to obtain any additional information the Company may possess or can obtain without unreasonable effort or expense that is necessary to verify the accuracy of the information furnished to such prospective Investor. No other persons have been authorized to give information or make any representations concerning this Offering, and, if given or made, such other information or representations much not be relied upon as having the authorized by the Company. Prospective Investors or Purchasers wishing to inquire about the Offering are invited to contact the Company at:

Garry McIntosh, Chief Operating Officer
1701 Directors Boulevard
Suite 110
Austin, Texas 78744
E-mail: garry@intivatoken.com
Phone: (844) 413-2602



ADDENDUM B


ReadyDoc™

Documents will not be stored in the Intiva Health Platform, only in Hashgraph.

Intiva Health Platform

Rest API

Hashgraph Platform



All "versions" of documents stay in the Hashgraph. Credentialing packages will be a point in time.

ADDENDUM B


ReadyDoc™

As the credential documents are continued to be used over time by numerous facilities (FMG) to authorize licensed medical professionals (LMP) to practice at facilities, the “reputation” of those documents authenticity and credibility grows.

Intiva Health Platform


Integration Layer

Hashgraph Platform



ADDENDUM C

Fragmentation



Only Hashgraph and SSL can get into nodes


Single Node

Holds document fragment	Rest	State
	Platform	Cache
	Block	

Rest: Rest API
Platform: Sends transaction to all other nodes
Block: Holds transaction history after consensus
State: State of node (still being determined)
Cache: Holds "state" after state is full

Document fragments are placed in random nodes

Two copies are made of each document shard and placed in two different nodes



API asks each node if they have a piece of document HGT123?



Response from each node


node	fragment
1	F,C
2	D
3	B,E
4	C
5	E,F
6	A,D
7	-
8	B
9	A



Document Reassembled





Document HGT123



ADDENDUM D


Roadmap and Milestones (Past)






ADDENDUM D

Roadmap and Milestones (Future)




All dates included herein are estimates based on the information currently available to the Company and are subject to change without notice to any prospective Investors or Purchasers.




ADDENDUM E

Token Issuance Plan




One half (0.5%) percent to two (2%) percent of the NTVA used in some transactions will be frozen for up to five (5) years. After the freeze period, these NTVA will be redistributed to users in order to continue Token Event rewards.



ADDENDUM F


Token Events

Activity on the Platform will be incentivized to LMPs in the following manner:



 = Token Event


Token Events - activities that result in NTVA rewards



ADDENDUM F


Token Events

Similarly, FMGs and Key Partners are incentivized to be active participants in the Platform in the following manner:




= Token Event

Token Events - activities that result in NTVA rewards




ADDENDUM F

Token Events



 = Token Event


Token Events - activities that result in NTVA rewards



ADDENDUM F

Token Events

The NTVA earned for the activities listed under “Time and Activity on Site” in the following chart will be further multiplied by time on site and repetitive activities. The NTVA earned for the activities listed under “Participation” in the following chart will be further multiplied by quantity or amount of activities.



Token Events - activities that result in NTVA rewards